×
Mogamulizumab for cutaneous T- cell lymphoma
https://ecancer.org/conference/942-ash-2017/video/6581/mogamulizumab-for-cutaneous-t--cell-lymphoma.php

Oct 12th, 2017 - Prof Kim presents, in a press conference at the ASH 2017 annual meeting, data from a randomized trial looking into mogamulizumab, a monoclonal antibody directed against chemokine receptor 4, for patients with cutaneous T- cell lymphoma.

Ibrutinib plus venetoclax for previously treated CLL: CLARITY trial
https://ecancer.org/conference/942-ash-2017/video/6577/ibrutinib-plus-venetoclax-for-previously-treated-cll--clarity-trial.php

Oct 12th, 2017 - Prof Hillmen speaks about the CLARITY trial looking at ibrutinib plus venetoclax in relapsed, refractory CLL

Dr. Davids on Checkpoint Blockade Inhibition in Hematologic Malignancies After Stem Cell Transplant
https://www.onclive.com/conference-coverage/ash-2017/dr-davids-on-checkpoint-blockade-inhibition-in-hematologic-malignancies-after-stem-cell-transplant

Oct 12th, 2017 - Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation.

Follow-Up Results for Ruxolitinib in the Second-Line Treatment of PV
https://www.targetedonc.com/conference/2017-ash-mpn/followup-results-for-ruxolitinib-in-the-secondline-treatment-of-pv

Dec 12th, 2017 - Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses 4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.

Could Single-Cell RNA Sequencing Help Personalize Multiple Myeloma Treatment?
http://www.cancernetwork.com/ash-street-team/could-single-cell-rna-sequencing-help-personalize-multiple-myeloma-treatment

This video highlights research that found that single-cell RNA sequencing can better characterize patients and potentially improve multiple myeloma treatment in a more personalized manner.

The Safety and Efficacy of Venetoclax/Obinutuzumab Combo in CLL
https://www.targetedonc.com/conference/2017-ash/the-safety-and-efficacy-of-venetoclaxobinutuzumab-combo-in-cll

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

HCT Consolidation Improves Survival in Younger MCL Patients
http://www.cancernetwork.com/ash-street-team/hct-consolidation-improves-survival-younger-mcl-patients

This video highlights results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant during first remission.

Dr. Berdeja Discusses Results for bb2121 in Multiple Myeloma
https://www.targetedonc.com/conference/2017-ash/dr-berdeja-discusses-results-for-bb2121-in-multiple-myeloma

Nov 12th, 2017 - Jesus Berdeja, MD, Director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses results of a study that explored bb2121, an anti-BCMA CAR T cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma during the 2017 ASH Annual Meeting.

Novel Agent Active in Refractory Polycythemia Vera
http://www.cancernetwork.com/ash-street-team/novel-agent-active-refractory-polycythemia-vera

This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.

Exploring Early Ibrutinib Intervention in High-Risk CLL
https://www.targetedonc.com/conference/2017-ash/exploring-early-ibrutinib-intervention-in-highrisk-cll

Sep 12th, 2017 - Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Adding Nivolumab to Induction Chemotherapy Safe in Younger AML Patients
http://www.cancernetwork.com/ash-street-team/adding-nivolumab-induction-chemotherapy-safe-younger-aml-patients

This video highlights a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia.

Mikkael A. Sekeres, MD, MS: Highlights of the 2017 ASH Annual Meeting
https://www.ashclinicalnews.org/multimedia/mikkael-sekeres-md-ms-highlights-2017-ash-annual-meeting/

Oct 12th, 2017 - ASH Clinical News Editor-in-Chief Mikkael A. Sekeres, MD, MS, shares some “must-see” sessions at the 2017 ASH Annual Meeting.

Immunotherapies Could Play Role in CALR-Positive Myeloproliferative Neoplasms
http://www.cancernetwork.com/myeloproliferative-neoplasms/immunotherapies-could-play-role-calr-positive-myeloproliferative-neoplasms

This video highlights a study that establishes mutated CALR as a myeloproliferative neoplasms–specific tumor antigen and provides a rationale for the development of immunotherapies targeting mutated CALR.

Real World' CAR T Cells: Comparing and Using Approved Products
https://www.medscape.com/viewarticle/891801

Feb 2nd, 2018 - Drs Perales and Pasquini discuss the rapidly advancing field of CAR T and how patient safety and choice can be managed during these unprecedented times.

Comparing CAR T-Cell Therapies in Lymphoma
https://www.medscape.com/viewarticle/891635

Drs Ann LaCasce and Caron Jacobson on how these and other treatments may change your practice in the new year.

Data from the CLARITY trial of ibrutinib plus venetoclax
https://ecancer.org/conference/942-ash-2017/video/6582/data-from-the-clarity-trial-of-ibrutinib-plus-venetoclax.php

Oct 12th, 2017 - Prof Hillmen presents, in a press conference at the 2017 ASH annual meeting, data from the CLARITY trial looking at ibrutinib plus venetoclax in relapsed, refractory CLL.

Data from the JULIET trial of CTL019 for relapsed or refractory diffuse large B-cell lymphoma
https://ecancer.org/conference/942-ash-2017/video/6586/data-from-the-juliet-trial-of-ctl019-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.php

Oct 12th, 2017 - Dr Schuster presents, in a press conference at the 2017 ASH annual meeting, data from the phase 2 JULIET trial looking at CTL019 (tisagenlecleucel) in adult patients with relapsed or refractory diffuse large B-Cell lymphoma.

Adding Nivolumab to Induction Chemotherapy Safe in Younger AML Patients
http://www.cancernetwork.com/ash-street-team/adding-nivolumab-induction-chemotherapy-safe-younger-aml-patients

This video highlights a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia.

Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
https://ecancer.org/conference/942-ash-2017/video/6583/brentuximab-vedotin-for-advanced-hodgkin-lymphoma-in-the-echelon-1-study.php

Oct 12th, 2017 - Dr Connors presents, in a press conference at the 2017 ASH annual meeting, data from the phase 3 Echelon-1 study looking at brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine as frontline therapy in patients with previously untreated stage III or IV hodgkin lymphoma.

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma
https://www.onclive.com/onclive-tv/dr-berdeja-discusses-next-steps-with-bb2121-in-multiple-myeloma

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.